Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for extensive-stage small cell lung cancer from the perspective of the healthcare system in China

Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for extensive-stage small cell lung cancer from the perspective of the healthcare system in China

BackgroundExtensive-stage small-cell lung cancer (ES-SCLC) poses a formidable challenge due to its aggressive nature and poor prognosis. While immune checkpoint inhibitors have shown promise as part of first-line therapy, their cost-effectiveness and survival benefits in the Chinese healthcare syste...

Full description

Saved in:
Bibliographic Details
Main Authors: Feng Chen, Xue Feng, Lin Lin Xiao, Hai Juan Tang, Shu Xia Qin, Jie Ping Peng, Jing Bai
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Public Health
Subjects:
small-cell lung cancer
immune checkpoint inhibitors
cost-effectiveness analysis
tislelizumab
first-line therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fpubh.2025.1552734/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items